Get an EU expert view on your EU readiness.
Start Europe on the right foot.
In one conversation, a senior AzurBio advisor asks the questions EMA will ask and points out what you may not have seen yet.
Get your EU expert read
Your advisor gets back to you within 2 business days to find a slot.
What you leave with
Your blind spots
The questions EMA is likely to raise on your asset that are not covered yet.
Your top priorities
Ranked by urgency and impact. For example, whether SME status applies to you and what it would save you in EMA fees.
Your next step
A short written note on your EU path, sent after the call.
38%
of EMA first-time applicants are hit by a Major Objection from CHMP.
Most of them were visible at month 0.
Who it’s for
- Your first medicine. A US or international biotech taking its first asset through development.
- Europe on the horizon. Your FDA path is taking shape, and the EU comes next.
- Any stage, ideally early. From preclinical to pivotal.
What it is not
- Not an audit. A conversation, with nothing to pass.
- Not a generic EU overview. Your asset, your data, your stage.
- Not a pitch. Useful whether or not we work together.
You can read about the EU market.
Or talk to people who built careers in it.
Every session is led by a senior advisor in regulatory affairs or market access, who has led EU launches in global pharma companies.
How it works
- 1. Tell us about your program
A short form about your program. Two minutes. - 2. We reach out
Your advisor gets back to you within 2 business days to find a slot. - 3. Leave with clarity
30 minutes on your case, then a short follow-up note by email.
Before EMA asks,
know what matters.
The earlier you ask, the more options you keep.